.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
When convulsive status epilepticus persists after benzodiazepines, clinicians need a rapid second-line treatment. The ESETT randomized trial compared levetiracetam, fosphenytoin and valproate in children, adults and older adults with established benzodiazepine-refractory status epilepticus. Across all three age groups, treatment success—defined by seizure cessation with improved consciousness and no additional antiseizure medication at one hour—occurred in roughly half of patients. No meaningful difference in efficacy was detected between the three agents, and serious safety outcomes were broadly comparable. The importance of ESETT is practical: it supports more flexible second-line selection when one agent is contraindicated, unavailable or less suitable for a particular patient. The trial also demonstrates that treatment failure after benzodiazepines remains common, emphasising the need for rapid escalation and close cardiorespiratory monitoring. For HCPs, the message is not to delay treatment while searching for a “best” second-line drug. Instead, clinicians can choose among evidence-supported options according to comorbidities, drug interactions, local availability and familiarity, while preparing for further escalation when seizures continue.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
When convulsive status epilepticus persists after benzodiazepines, clinicians need a rapid second-line treatment. The ESETT randomized trial compared levetiracetam, fosphenytoin and valproate in children, adults and older adults with established benzodiazepine-refractory status epilepticus. Across all three age groups, treatment success—defined by seizure cessation with improved consciousness and no additional antiseizure medication at one hour—occurred in roughly half of patients. No meaningful difference in efficacy was detected between the three agents, and serious safety outcomes were broadly comparable. The importance of ESETT is practical: it supports more flexible second-line selection when one agent is contraindicated, unavailable or less suitable for a particular patient. The trial also demonstrates that treatment failure after benzodiazepines remains common, emphasising the need for rapid escalation and close cardiorespiratory monitoring. For HCPs, the message is not to delay treatment while searching for a “best” second-line drug. Instead, clinicians can choose among evidence-supported options according to comorbidities, drug interactions, local availability and familiarity, while preparing for further escalation when seizures continue.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
4 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
5 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
4 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
